Response to nilotinib as a first-line treatment for metastatic gastrointestinal stromal tumors

Journal of Gastrointestinal Cancer

Volumn 43, Issue 2, 2012, Pages 385-387

  Schlemmer, Marcus ^a,c   Schinwald, Nicole ^a   Bruns, Christiane ^a   Berger, Frank ^a   Reichardt, Peter ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b HELIOS Klinikum Bad Saarow   (Germany)

^c Campus Grosshadern   (Germany)

Author keywords

GIST; Imatinib; Nilotinib; TKI

Indexed keywords

IMATINIB; NILOTINIB;

ADULT; ARTICLE; CANCER SURGERY; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LIVER FUNCTION; LIVER METASTASIS; LIVER SURGERY; PERITONEUM METASTASIS; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; LIVER NEOPLASMS; PERITONEAL NEOPLASMS; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PYRIMIDINES;

EID: 84863860547     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-010-9208-2     Document Type: Article

References (5)

1. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127-34. (Pubitemid 39296599)
2. Gramza AW, Corless CL, Heinrich MC. Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin Cancer Res. 2009;15:7510-8.
3. Montemurro M, Schöffski P, Reichardt P, et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer. 2009;45:2293-7.
4. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130:1466-78. (Pubitemid 44520713)
5. Manley PW, Drueckes P, Fendrich G, et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta. 2010;1804:445-53. Epub 2009; Nov 14.